BioXcel has entered into a partnership with Takeda Development Center Americas for the repurposing of assets across the gamut of rare diseases.
Through this partnership, Takeda will gain access to and leverage BioXcel's Big Data Innovation Lab – an integrated product discovery engine – and PharmGPS Orphan Disease Suite for drug discovery and repurposing.
|Searching for more deal information? Current Partnering offers the following options:
Commenting on the partnership, BioXcel's CEO and Chairman, Vimal Mehta, Ph.D., said, "We are pleased that Takeda will leverage our expertise in rare and ultra rare diseases to support their innovation and portfolio expansion initiatives. Discovering novel applications for existing molecules is an increasingly attractive strategy to address patient needs, while capitalizing on previous investments and de-risking clinical development. Our Big Data Innovation Lab facilitates the repurposing of the most attractive candidates applicable to a given disease."
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2015
View: Top biotech companies